Oral consumption of PLX5662, a more brain-penetrant CSF-1R inhibitor than PLX3397, produces no alterations in consummatory behavior or weight gain in mice, while genetic activation of microglia by tumor necrosis factor a-induced protein 3 (TNFAIP3) causes obesity [9]. Here, CSF1R is linked to obesity disorder.